
Opinion|Videos|August 15, 2024
Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Briefly comment on the recent FDA accelerated approval granted to pirtobrutinib based on findings from BRUIN.
- How are you currently using pirtobrutinib in the clinical practice setting and how do you sequence it with other available therapies?
- Is there a potential role for pirtobrutinib in earlier lines of therapy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5





































